Tirzepatide acts on GIP and GLP-1 receptors, while semaglutide acts on GLP-1 receptors
Its thought that GLP-1 agonists promote weight loss through some combination of appetite suppression, feeling full faster and for longer, and/or slowing the movement of food from the stomach to the small intestine
Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension
In addition to a heightened risk of pancreatitis and gallstones, Wegovy patients have also suffered from: Severe and Prolonged Bouts of Vomiting Occasional nausea and vomiting while on Wegovy is normal
The combination of an NSAID with an ACE inhibitor or ARB and a diuretic (the "triple whammy") significantly increases acute kidney injury risk, especially if dehydration occurs from semaglutide-related GI effects
All experiments were performed in line with German animal welfare laws as well as institutional guidelines and were reported to the responsible authorities (Vorabmeldung VM2023-16 and previous notifications)
